Norliqva is a drug owned by Cmp Development Llc. It is protected by 4 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 24, 2041. Details of Norliqva's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12005141 | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | Active |
| US11723866 | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | Active |
| US11253474 | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | Active |
| US11458095 | Pharmaceutical solution of amlodipine |
Feb, 2041
(16 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Norliqva's patents.
Latest Legal Activities on Norliqva's Patents
Given below is the list of recent legal activities going on the following patents of Norliqva.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Electronic Review Critical | 15 Aug, 2023 | US11723866 |
| Recordation of Patent eGrant | 15 Aug, 2023 | US11723866 |
| Recordation of Patent Grant Mailed Critical | 15 Aug, 2023 | US11723866 |
| Mail Patent eGrant Notification | 15 Aug, 2023 | US11723866 |
| Email Notification Critical | 15 Aug, 2023 | US11723866 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Aug, 2023 | US11723866 |
| Patent eGrant Notification | 15 Aug, 2023 | US11723866 |
| Email Notification Critical | 27 Jul, 2023 | US11723866 |
| Electronic Review Critical | 27 Jul, 2023 | US11723866 |
| Issue Notification Mailed Critical | 26 Jul, 2023 | US11723866 |
US patents provide insights into the exclusivity only within the United States, but Norliqva is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Norliqva's family patents as well as insights into ongoing legal events on those patents.
Norliqva's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Norliqva's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 24, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Norliqva Generic API suppliers:
Amlodipine Besylate is the generic name for the brand Norliqva. 36 different companies have already filed for the generic of Norliqva, with Invagen Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Norliqva's generic
Alternative Brands for Norliqva
Norliqva which is used for the symptomatic treatment of chronic stable angina and confirmed or suspected vasospastic angina., has several other brand drugs using the same active ingredient (Amlodipine Besylate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Adhera |
| ||||
| Boehringer Ingelheim |
| ||||
| Cosette |
| ||||
| Novartis |
| ||||
| Pharmacia |
| ||||
| Purple Biotech |
| ||||
| Sandoz |
| ||||
| Synthon Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Amlodipine Besylate, Norliqva's active ingredient. Check the complete list of approved generic manufacturers for Norliqva
About Norliqva
Norliqva is a drug owned by Cmp Development Llc. It is used for the symptomatic treatment of chronic stable angina and confirmed or suspected vasospastic angina. Norliqva uses Amlodipine Besylate as an active ingredient. Norliqva was launched by Cmp Dev Llc in 2022.
Approval Date:
Norliqva was approved by FDA for market use on 24 February, 2022.
Active Ingredient:
Norliqva uses Amlodipine Besylate as the active ingredient. Check out other Drugs and Companies using Amlodipine Besylate ingredient
Treatment:
Norliqva is used for the symptomatic treatment of chronic stable angina and confirmed or suspected vasospastic angina.
Dosage:
Norliqva is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1MG BASE/ML | SOLUTION | Prescription | ORAL |